GREENLAND MINES LTD
GRMLNASDAQ🏆 #4602 by market capUS Equity
$370.22▲ $5.26 (+1.42%)
Simulated priceTrack GRML
Get earnings, price moves & breaking news on Telegram
24h▲ 1.4%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$36M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
72
Fair
No chart data available for GRML.
Trading Snapshot
- Day Range
- $368.71 – $372.16
- 52-Week Range
- $0.16 – $18.08
- Volume
- $3.81B
- Avg Volume
- $3.65B
- Shares Outstanding
- 3.0M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $845,367
- P/E Ratio
- -1.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-8.60
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +167.9%
Why Investors Own GRML
- ✓High-growth profile — revenue up +32.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 52% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GREENLAND MINES LTD
GRMLFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$7M▲ +29.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▲ +107.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.5M▲ +167.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▲ +$7M YoY
StockOtter · stockotter.spaceAbout GREENLAND MINES LTD
Greenland Mines Ltd. (GRML) focuses on developing innovative therapeutic solutions to combat neurodegenerative diseases. The company's primary treatment modalities involve cutting-edge cell and gene therapies. Joseph Sinkule founded this enterprise on August 2, 2004, and its corporate operations are based in Omaha, Nebraska.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100
Analyst Price Target
ⓘAverage Target
$414.52
▲ +12.0% Upside
High Target$510.03
Low Target$331.40
Based on 41 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
GREENLAND MINES LTD tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift GRML price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
GREENLAND MINES LTD announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.